Genosyl Patent Expiration

Genosyl is a drug owned by Vero Biotech Inc. It is protected by 25 US drug patents filed from 2020 to 2023. Out of these, 13 drug patents are active and 12 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 22, 2040. Details of Genosyl's patents and their expiration are given in the table below.

Patent strength
4
/ 10

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11672938 Start-up protocols for nitric oxide delivery device
Jul, 2040

(13 years from now)

Active
US10213572 Nitrogen dioxide storage cassette
Feb, 2036

(9 years from now)

Active
US10737051 Nitrogen dioxide storage device
Oct, 2035

(9 years from now)

Active
US8607785 Systems and devices for generating nitric oxide
Jul, 2030

(3 years from now)

Active
US11103669 Nitric oxide therapies
Jun, 2030

(3 years from now)

Active
US11511252 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Sep, 2029

(2 years from now)

Active
US10926054 Systems and devices for generating nitric oxide
Aug, 2029

(2 years from now)

Active
US9604028 Systems and devices for generating nitric oxide
Aug, 2029

(2 years from now)

Active
US8944049 Systems and devices for generating nitric oxide
Aug, 2029

(2 years from now)

Active
US9701538 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2029

(2 years from now)

Active
US7560076 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Apr, 2027

(6 months from now)

Active
US7618594 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2026

(9 days from now)

Active
US7947227 Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2026

(9 days from now)

Active
US8057742 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Jan, 2026

(8 months ago)

Expired
US10814092 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Oct, 2025

(11 months ago)

Expired
US9522249 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US11554241 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US9956373 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US8609028 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US11383059 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US8226916 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US10124142 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US11291793 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US8821801 Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(1 year, 1 month ago)

Expired
US6758214 Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
Feb, 2022

(4 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Genosyl's patents.

Given below is the list of recent legal activities going on the following patents of Genosyl.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 02 Mar, 2026 US11383059
Email Notification 05 Feb, 2026 US8607785
Email Notification 05 Feb, 2026 US8609028
Change in Power of Attorney (May Include Associate POA) 05 Feb, 2026 US8609028
Change in Power of Attorney (May Include Associate POA) 05 Feb, 2026 US8607785
Email Notification 11 Dec, 2025 US11103669
Change in Power of Attorney (May Include Associate POA) 11 Dec, 2025 US9604028
Change in Power of Attorney (May Include Associate POA) 11 Dec, 2025 US11103669
Email Notification 11 Dec, 2025 US9604028
Maintenance Fee Reminder Mailed 24 Nov, 2025 US11291793

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Genosyl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Genosyl's family patents as well as insights into ongoing legal events on those patents.

Genosyl's Family Patents

Genosyl has patent protection in a total of 5 countries. It has a significant patent presence in the US with 62.1% of its patents being US patents. Click below to unlock the full patent family tree for Genosyl.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Genosyl:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma Université de Sherbrooke NA RECRUITING
(Sep 1, 2026)
PHASE3
NO During CPB in Neonates to Reduce Risk of AKI Children's Hospital Medical Center, Cincinnati NA RECRUITING
(Aug 1, 2026)
PHASE3
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women Colorado State University NA COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2
Nitrite Supplementation in Long COVID Patients VA Office of Research and Development NA COMPLETED
(Aug 1, 2026)
PHASE2
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults UConn Health NA RECRUITING
(Aug 1, 2026)
PHASE2
Beetroot Juice for Boosting Immunity During a Time of Stress. Baylor University NA COMPLETED
(Aug 1, 2026)
PHASE2
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers Regina Elena Cancer Institute NA RECRUITING
(Aug 1, 2026)
PHASE3
Genistein for the Reduction of Adverse Cardiovascular Events (GRACE) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
Ginger's Therapeutic Potential in Asthma Emily DiMango, MD NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD University of Alberta NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD University of Alberta NA RECRUITING
(Jul 1, 2026)
PHASE2
The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) NA COMPLETED
(Jul 1, 2026)
PHASE2
Response to Exercise and Nitric Oxide in PAD Northwestern University NA RECRUITING
(Jul 1, 2026)
PHASE2
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression West China Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants NICHD Neonatal Research Network NA COMPLETED
(Jun 1, 2026)
PHASE3
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation Montreal Heart Institute NA RECRUITING
(Jun 1, 2026)
PHASE2
Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury University of Pennsylvania NA ENROLLING BY INVITATION
(Jun 1, 2026)
PHASE2
Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease University Hospital, Rouen NA RECRUITING
(Jun 1, 2026)
PHASE2
Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH University Hospital, Brest NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
Effect of a Daily Supplement on Plasma PAI-1 Levels University of California, Los Angeles NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans Vanderbilt University Medical Center NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2
The COCOA-PAD II Trial Northwestern University NA RECRUITING
(May 1, 2026)
PHASE3
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF) Washington University School of Medicine NA RECRUITING
(May 1, 2026)
PHASE2
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH VA Office of Research and Development NA RECRUITING
(May 1, 2026)
PHASE2
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers NOxy Health Products, LLC NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass Xijing Hospital NA RECRUITING
(May 1, 2026)
PHASE3
Impact of Prasterone on Cardiometabolic Indicators in Perimenopausal Women. Universidad de Guanajuato NA COMPLETED
(May 1, 2026)
PHASE3
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication Louis Messina NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1
NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI Simon Fraser University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2
Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy Wake Forest University Health Sciences NA RECRUITING
(Apr 1, 2026)
PHASE1
Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis Sanotize Research and Development corp. NA COMPLETED
(Apr 1, 2026)
PHASE2
Vasodilator and Exercise Study for DMD (VASO-REx) University of Florida NA RECRUITING
(Apr 1, 2026)
PHASE2
Novel Approaches for Improving Vascular Function in Veterans With HFpEF VA Office of Research and Development NA RECRUITING
(Apr 1, 2026)
PHASE1
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease Suvankar Majumdar NA RECRUITING
(Apr 1, 2026)
PHASE2
Phase Ib of L-NMMA and Pembrolizumab The Methodist Hospital Research Institute NA COMPLETED
(Mar 1, 2026)
PHASE1
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 Massachusetts General Hospital NA TERMINATED
(Mar 1, 2026)
PHASE2
NO Prevention of COVID-19 for Healthcare Providers Massachusetts General Hospital NA TERMINATED
(Mar 1, 2026)
PHASE2
Effect of iNO in Patients With Submassive and Massive PE University of California, Los Angeles NA WITHDRAWN
(Mar 1, 2026)
PHASE2
L-Citrulline and Endothelial Function University of Oklahoma NA COMPLETED
(Mar 1, 2026)
PHASE1
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) Thirty Respiratory Limited NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
iNO300 Therapy in Critically Ill Patients With Pneumonia Massachusetts General Hospital NA RECRUITING
(Mar 1, 2026)
EARLY PHASE1
Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction Ankara City Hospital Bilkent NA RECRUITING
(Mar 1, 2026)
PHASE2, PHASE3




Generic Launch

Generic Release Date:

Genosyl's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 22, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Genosyl Generic API suppliers:

Nitric Oxide is the generic name for the brand Genosyl. 2 different companies have already filed for the generic of Genosyl, with Vero Biotech Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Genosyl's generic

Alternative Brands for Genosyl

Genosyl which is used for treating pulmonary hypertension or hypoxia through nitric oxide delivery to the patient., has several other brand drugs using the same active ingredient (Nitric Oxide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Mallinckrodt Ireland
Inomax


Apart from brand drugs containing the same ingredient, some generics have also been filed for Nitric Oxide, Genosyl's active ingredient. Check the complete list of approved generic manufacturers for Genosyl





About Genosyl

Genosyl is a drug owned by Vero Biotech Inc. It is used for treating pulmonary hypertension or hypoxia through nitric oxide delivery to the patient. Genosyl uses Nitric Oxide as an active ingredient. Genosyl was launched by Vero in 2019.

Approval Date:

Genosyl was approved by FDA for market use on 20 December, 2019.

Active Ingredient:

Genosyl uses Nitric Oxide as the active ingredient. Check out other Drugs and Companies using Nitric Oxide ingredient

Treatment:

Genosyl is used for treating pulmonary hypertension or hypoxia through nitric oxide delivery to the patient.

Dosage:

Genosyl is available in gas form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
800PPM GAS Prescription INHALATION